Celestica (CLS) Q1 2026 Earnings Transcript

Celestica reported Q1 revenue of $4.05 billion, up 53%, with adjusted EPS of $2.16, up 80% and above the high end of guidance, while adjusted operating margin reached a record 8.0%. Management raised full-year 2026 revenue guidance to $19 billion from $17 billion and adjusted EPS to $10.15 from $8.75, citing strong hyperscaler-driven demand in CCS, new 1.6T/CPO networking wins, and robust AI/ML compute ramps. The main offset is tighter component supply and rising input costs, but the company still expects strong 2027 growth and maintained $1 billion of 2026 CapEx with over $2 billion of liquidity available.

Analysis

Celestica is no longer being traded as a normal EMS/industrial hardware name; it is becoming a supply-constrained, design-in compounder tied to hyperscaler capex. The second-order implication is that the bottleneck has shifted from demand discovery to allocation of scarce inputs, which tends to favor the few vendors with multi-year NCNR coverage, systems-level engineering depth, and the balance sheet to pre-fund inventory. That combination should continue to compress the competitive field and widen share gaps versus smaller ODM/contract manufacturers that cannot carry the same working-capital load or qualify for the most complex next-gen programs.

The market may still be underestimating how much of the growth is de-risked by contract structure rather than just enthusiasm around AI. Long-lead silicon and customer-backed capacity commitments create a visibility profile that can extend well beyond the next four quarters, and that matters because it lowers the probability that a temporary supply hiccup becomes a demand reset. The flip side is that rising component costs and higher CapEx can create near-term margin noise even while revenue accelerates; this is a quality-of-earnings issue, not a thesis-breaker, but it means the stock can remain volatile around quarters where inventory builds outpace cash conversion.

The biggest technical risk is not customer demand rolling over; it is execution slippage during simultaneous ramps across 800G, 1.6T, CPO, and rack-scale compute. If a few key components stay tight longer than expected, revenue gets pushed right, not cancelled, which can still hit sentiment because the street will likely extrapolate delays into 2027 capacity risk. Conversely, any evidence that supply catches up faster than planned would likely trigger an additional re-rate because it would pull forward both margin leverage and FCF inflection.

The contrarian view is that consensus may be treating the story as already "priced in" because the stock has rerated, but the bigger mispricing could be the duration of the earnings power. The strongest setup is not just 2026 upside; it is the combination of 2027 visibility, improving mix from higher-value programs, and optionality from scale-up architectures where Celestica appears to be moving up the value chain. That should keep the multiple supported unless the market starts to believe supply-chain inflation is structurally eroding incremental returns on capital.

Key Decisions for Investors

• Long CLS outright on a 3-6 month horizon; use pullbacks on supply-chain scare headlines as entry points. Risk/reward remains attractive as the near-term issue is timing, while the medium-term catalyst is 2027 program conversion and margin leverage.
• Buy CLS Jan-2027 call spreads to express the view that earnings power extends into next year without paying full premium for near-term volatility. This captures rerating potential if the market starts capitalizing 2027 visibility rather than just 2026 guidance.
• Pair long CLS / short a lower-quality EMS or hardware assembler with weaker customer concentration and less scale in advanced networking. The trade benefits from capital allocation advantages and should widen if supply constraints continue to favor the largest, best-capitalized operators.
• For tactical traders, use options around next quarter: sell puts into any broad AI hardware selloff if implied vol spikes on component shortage fears. The core thesis is that delays should defer, not destroy, demand.
• Avoid chasing a full position after a sharp gap-up; stage in over 2-4 weeks because the stock is likely to trade around supply headlines even while the fundamental trend stays positive.